Founded in 2018, Hanno Medical specializes in research and development of extracorporeal life support systems and related medical devices. The company says it has cracked core ECLS technologies and achieved independent production and mass production of key components. On January 4, 2023 its domestically developed first complete extracorporeal membrane oxygenation (ECMO) system received regulatory approval. In July 2023 the company received approvals for two additional core products: a disposable centrifugal pump head and a disposable long‑acting membrane oxygenator. With four approved products, Hanno quickly promoted them in the domestic market. The company recently received additional financing after completing an E round in December 2023 that exceeded ¥100 million. Hanno Medical is a biotechnology services firm engaged in technology development, consulting, and technical services across biological and medical sciences. Its product portfolio includes the 'Lifemotion' (心动力) portable life emergency rescue system, an innovation and R&D project. The company combines R&D efforts with service offerings for medical and biological technology applications. Recently it secured new institutional capital, signaling continued investor interest in its development roadmap. The reported financing was an E round exceeding ¥100 million. Lead investors named in the report include the Guangdong TCM Health Fund managed by Guokai Financial and Guangdong Hengjian Holdings, with participation from Zhejiang Provincial Development Asset Management and Huashi Capital.

Total raised

$14M

Funding rounds

2

Latest round

Series E

Latest activity

Jan 2024